tiprankstipranks
Summit Therapeutics (SMMT)
NASDAQ:SMMT
US Market
Holding SMMT?
Track your performance easily

Summit Therapeutics (SMMT) Ownership - Who Owns Summit Therapeutics?

1,027 Followers

Summit Therapeutics (SMMT) Ownership Overview

80.14%2.60%4.32%2.54%10.40%
80.14% Insiders
4.32% Other Institutional Investors
2.54% ETFs
10.40% Public Companies and Individual Investors
The ownership structure of Summit Therapeutics (SMMT) stock is a mix of institutional, retail, and individual investors. Approximately 9.46% of the company’s stock is owned by Institutional Investors, 80.14% is owned by Insiders, and 10.40% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Oct 03, 2024
Maky Zanganeh
Co Ceo,director
xxxxxxxxxxxxx
$498776
Mar 27, 2024
Maky Zanganeh
Co Ceo,director
xxxxxxxxxxxxx
$411094
Mar 27, 2024
xxxxxxxxxxxxx
$375000
Dec 13, 2023
Maky Zanganeh
Co Ceo,director
xxxxxxxxxxxxx
$1204108

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Sep 30, 2024
xxxxxxxxxxxxx
$348385
Sep 30, 2024
xxxxxxxxxxxxx
$534904543

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
551,695,096Insider74.81%10,482,206,824
35,738,442Insider4.85%679,030,398
24,424,865Institution3.31%464,072,435
10,602,633Institution1.44%201,450,027
7,752,569Institution1.05%147,298,811
4,784,429Institution0.65%90,904,151
4,767,685Institution0.65%90,586,015
3,020,242Insider0.41%57,384,598
1,664,374Institution0.23%31,623,106
1,284,354Institution0.17%24,402,726

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
7,752,569Institution1.05%147,298,811
4,784,429Institution0.65%90,904,151
1,664,374Institution0.23%31,623,106
992,476Institution0.13%18,857,044
850,583Institution0.12%16,161,077
750,000Institution0.10%14,250,000
537,522Institution0.07%10,212,918
525,834Institution0.07%9,990,846
442,474Institution0.06%8,407,006
272,395Institution0.04%5,175,505

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
3,413,126Institution0.46%63,450,012
2,723,152Institution0.37%50,623,396
2,395,083Institution0.32%45,506,577
2,049,550Institution0.28%38,101,135
1,842,161Institution0.25%34,245,773
1,148,567Institution0.16%21,156,604
750,677Institution0.10%14,262,863
666,548Institution0.09%12,277,814
596,123Institution0.08%11,326,337
399,016Institution0.05%7,417,707

FAQ

Who Owns Summit Therapeutics (SMMT)?
According to the latest TipRanks data, approximately 4.32% of the company's stock is held by institutional investors, 80.14% is held by insiders, and 10.40% is held by retail investors.
    What percentage of Summit Therapeutics (SMMT) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 4.32% of Summit Therapeutics (SMMT) stock is held by institutional investors.
      What percentage of Summit Therapeutics (SMMT) stock is held by retail investors?
      According to the latest TipRanks data, approximately 10.40% of Summit Therapeutics (SMMT) stock is held by retail investors.
        Who owns the most shares of Summit Therapeutics (SMMT)?
        Robert Duggan owns the most shares of Summit Therapeutics (SMMT).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis